SCHEMBL17099478

SCHEMBL17099478

CC1(C)Cc2ccc(Br)cc2N1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 1/20 0.46
▸ AHR P35869 1/20 0.46
▸ PGR P06401 2/20 0.40
▸ PNMT P11086 4/20 0.40
▸ ADRA2A P08913 3/20 0.40
▸ ADRA2B P18089 3/20 0.40
▸ ADRA2C P18825 3/20 0.40
▸ ASIC3 Q9UHC3 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ GFER P55789 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ BRD4 O60885 1/20 0.38
▸ GAA P10253 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ TDP2 O95551 1/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31394401 0.86 BRD4 (0.46) CMA1AHRPGRPNMTADRA2A
Isobutyramide SCHEMBL17099457 0.85 HPGD (0.39) CMA1AHRPNMTADRA2AADRA2B
SCHEMBL20617808 0.78 HTR5A (0.43) ADRA2AHPGDGFERHSD17B10ALDH1A1
SCHEMBL9082663 0.78 CMA1 (0.43) CMA1AHRPGRPNMTADRA2A
SCHEMBL12280375 0.76 PNMT (0.50) CMA1AHRPNMTADRA2AADRA2B
SCHEMBL15188950 0.73 APP (0.44) CMA1AHRPGRPNMTADRA2A
SCHEMBL30512977 0.72 HTT (0.58) CMA1AHRPGRHPGDGFER
SCHEMBL1119036 0.71 GAA (0.46) AHRPGRHPGDALDH1A1BRD4
SCHEMBL19155889 0.71 HTR5A (0.42) ADRA2AHPGDGFERHSD17B10ALDH1A1
SCHEMBL5328438 0.70 AR (0.47) PGRPNMTASIC3BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015143376-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS NIVALIS THERAPEUTICS, INC. (US) 2015-09-24 — — WO disclosed
Send feedback